Relapsed or refractory follicular lymphoma
FDA Acceptance of sNDA for Fifth BRUKINSA Indication Announced by BeiGene
SG Tylor
Source – Beigene BeiGene, a prominent global biotechnology company, made a groundbreaking announcement today. The US Food and Drug Administration ...
